Article

Urology Times, Digital Edition, May 2010

Related Videos
Thomas Powles, MBBS, MRCP, MD, on efficacy of sasanlimab plus BCG in BCG-naïve NMIBC
Thomas Powles, MBBS, MRCP, MD, on efficacy of sasanlimab plus BCG in BCG-naïve NMIBC
1 expert in this video
Using Ultrasensitive PSA Assays in Routine Practice
1 expert in this video
Ultra-Low PSA Response as a Trial End Point or Clinical Decision Point
1 expert is featured in this series.
Outcomes in Black patients receiving darolutamide plus ADT for mHSPC
2 experts are featured in this series.
Key Benefits of PET in ccRCC Risk Stratification
4 experts in this video
Case 2: A 68-Year-Old Woman With Non–Muscle-Invasive Bladder Cancer
2 experts are featured in this series.
Early Detection of ccRCC
1 expert is featured in this series.
Comparing the safety profile of darolutamide with other androgen receptor inhibitors in Black patients
Andrew Armstrong, MD, shares 5-year data on enzalutamide plus ADT in mHSPC
Andrew Armstrong, MD, shares 5-year data on enzalutamide plus ADT in mHSPC
Professor Dickon Hayne on bladder cancer data to watch for at ASCO 2025
Professor Dickon Hayne on bladder cancer data to watch for at ASCO 2025
Related Content
Rana R. McKay, MD, FASCO
June 4th 2025

COMRADE: Olaparib plus radium-223 improves rPFS in mCRPC

Benjamin P. Saylor
“This was a positive study, resulting in a statistically significant improvement in the primary end point of rPFS in the intent-to-treat population," said Rana R. McKay, MD, FASCO.
Pearls & Perspectives: Understanding and Improving Pelvic Health, with Diane Newman, DNP
June 2nd 2025

Pearls & Perspectives: Understanding and Improving Pelvic Health, with Diane Newman, DNP

Amy M. Pearlman, MD
Enzalutamide plus ADT continues to show durable survival benefit in mHSPC at 5 years
June 3rd 2025

Enzalutamide plus ADT continues to show durable survival benefit in mHSPC at 5 years

Hannah Clarke
According to the authors, these data continue to support enzalutamide plus ADT as a standard-of-care for patients with mHSPC.
Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD
May 17th 2025

Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD

Amy M. Pearlman, MD Alex Tatem, MD
Explore the latest insights on testosterone therapy, its benefits, and practical applications from leading urologists in men's health.
Michael Ong, MD
June 3rd 2025

Subgroup analysis evaluates darolutamide in previously treated mCRPC

Benjamin P. Saylor
Clinical benefit rate was observed 5 (27%) patients in cohort 1, 7 (27%) patients in cohort 2, and 2 (11%) patients in cohort 3.
Alicia Morgans, MD, MPH
June 3rd 2025

Phase 3 ARASTEP study to evaluate PSMA PET-CT–detected BCR in prostate cancer

Benjamin P. Saylor
“As of April 2025, 616 patients have been randomized,” said Alicia Morgans, MD, MPH.
© 2025 MJH Life Sciences

All rights reserved.